Arts E
Mol Ther. 2025; 33(2):427-429.
PMID: 39842428
PMC: 11852662.
DOI: 10.1016/j.ymthe.2025.01.001.
Govindan R, Stephenson K
Vaccines (Basel). 2024; 12(9).
PMID: 39340073
PMC: 11435826.
DOI: 10.3390/vaccines12091043.
Julg B, Walker-Sperling V, Wagh K, Aid M, Stephenson K, Zash R
Nat Med. 2024; 30(12):3534-3543.
PMID: 39266747
PMC: 11645281.
DOI: 10.1038/s41591-024-03247-5.
Williamson B, Wu L, Huang Y, Hudson A, B Gilbert P
PLoS One. 2024; 19(9):e0310042.
PMID: 39240995
PMC: 11379218.
DOI: 10.1371/journal.pone.0310042.
Karsten C, Buettner F, Cajic S, Nehlmeier I, Roshani B, Klippert A
PLoS Pathog. 2024; 20(5):e1012190.
PMID: 38805549
PMC: 11161069.
DOI: 10.1371/journal.ppat.1012190.
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S
Clin Microbiol Rev. 2024; 37(2):e0015222.
PMID: 38687039
PMC: 11324036.
DOI: 10.1128/cmr.00152-22.
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K
Proc Natl Acad Sci U S A. 2024; 121(4):e2308942121.
PMID: 38241441
PMC: 10823214.
DOI: 10.1073/pnas.2308942121.
Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.
Williamson B, Wu L, Huang Y, Hudson A, B Gilbert P
bioRxiv. 2024; .
PMID: 38168308
PMC: 10760080.
DOI: 10.1101/2023.12.14.571616.
Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana.
Moraka N, Choga W, Pema M, Chawawa M, Gobe I, Mokomane M
Sci Rep. 2023; 13(1):18134.
PMID: 37875518
PMC: 10598268.
DOI: 10.1038/s41598-023-44722-2.
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure.
Suphaphiphat K, Desjardins D, Lorin V, Dimant N, Bouchemal K, Bossevot L
Nat Commun. 2023; 14(1):6224.
PMID: 37803011
PMC: 10558491.
DOI: 10.1038/s41467-023-41966-4.
Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research.
Williamson B, Magaret C, Karuna S, Carpp L, Gelderblom H, Huang Y
iScience. 2023; 26(9):107595.
PMID: 37654470
PMC: 10466901.
DOI: 10.1016/j.isci.2023.107595.
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin.
Vamva E, Ozog S, Leaman D, Cheng R, Irons N, Ott A
Mol Ther Methods Clin Dev. 2023; 28:366-384.
PMID: 36879849
PMC: 9984920.
DOI: 10.1016/j.omtm.2023.02.004.
Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings.
Boswell K, Watkins T, Cale E, Samsel J, Andrews S, Ambrozak D
Front Immunol. 2022; 13:1087018.
PMID: 36582240
PMC: 9794141.
DOI: 10.3389/fimmu.2022.1087018.
Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T, Gumede N, Ndlovu B, Ndlovu S, Mann J, Chopera D
J Virol. 2022; 96(24):e0127022.
PMID: 36453881
PMC: 9769376.
DOI: 10.1128/jvi.01270-22.
Rational Engineering of a Sub-Picomolar HIV-1 Blocker.
Secchi M, Vangelista L
Viruses. 2022; 14(11).
PMID: 36366513
PMC: 9695723.
DOI: 10.3390/v14112415.
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
Moshoette T, Papathanasopoulos M, Killick M
Virol J. 2022; 19(1):143.
PMID: 36071449
PMC: 9450465.
DOI: 10.1186/s12985-022-01876-1.
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation.
Barnes C, Schoofs T, Gnanapragasam P, Golijanin J, Huey-Tubman K, Gruell H
Sci Adv. 2022; 8(32):eabp8155.
PMID: 35960796
PMC: 9374330.
DOI: 10.1126/sciadv.abp8155.
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing.
Walker L, Shiakolas A, Venkat R, Liu Z, Wall S, Raju N
Front Immunol. 2022; 13:855772.
PMID: 35401559
PMC: 8984479.
DOI: 10.3389/fimmu.2022.855772.
Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs.
Wang C, Schlub T, Yu W, Tan C, Stefic K, Gianella S
Clin Infect Dis. 2022; 75(8):1342-1350.
PMID: 35234862
PMC: 9555844.
DOI: 10.1093/cid/ciac164.
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
Mahomed S, Garrett N, Capparelli E, Osman F, Harkoo I, Yende-Zuma N
J Infect Dis. 2022; 226(3):510-520.
PMID: 35134995
PMC: 9417124.
DOI: 10.1093/infdis/jiac041.